Repare Therapeutics Inc., a clinical-stage precision oncology company, has announced an exclusive worldwide licensing agreement with Debiopharm International S.A. for lunresertib, a first-in-class PKMYT1 inhibitor. Under the terms of the agreement, Repare will receive a $10 million upfront payment and may receive up to $257 million in potential milestones, along with single-digit royalties on global net sales. This agreement builds on the existing collaboration between Repare and Debiopharm to explore the synergy of lunresertib with Debio 0123, a selective WEE1 inhibitor. Debiopharm will assume sponsorship of the MYTHIC study and manage future development activities for lunresertib. Two ongoing Phase 1 trials, the LIONS trial and the POLAR trial, are expected to have readouts in the second half of 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.